Compugen to Present Research at the Single Cell Genomics 2025 Conference
Rhea-AI Summary
Compugen (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company, will present research at the Single Cell Genomics 2025 Conference in Stockholm, Sweden from September 15-17, 2025. The presentation will showcase the company's AI/ML-powered computational capabilities in analyzing spatial context of cancer biology.
Dr. Roy Granit, Senior Director and Head of Computational Discovery, will present research titled "Bin2Niche: A spatial transcriptomics framework reveals immune-defined epithelial niches in MSI colorectal cancer" on September 15, 2025, at 2:10 PM CET. The poster presentation (ID: P035) will be available on Compugen's website after the conference.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CGEN gained 1.40%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
HOLON,
This research reflects Compugen's computational capabilities in understanding the spatial context of complex cancer biology that may inform drug discovery efforts and therapeutic strategies to potentially provide benefit to cancer patients.
Poster and short talk details:
Title: Bin2Niche: A spatial transcriptomics framework reveals immune-defined epithelial niches in MSI colorectal cancer
Presenting author: Roy Granit, Ph.D., Senior Director, Head of Computational Discovery, Compugen
Poster ID: P035
Date of presentation: September 15, 2025, at 2:10 PM CET
Poster will be available in the publications section of Compugen's website, www.cgen.com, following presentation.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
Vice President, Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-present-research-at-the-single-cell-genomics-2025-conference-302548838.html
SOURCE Compugen Ltd.
FAQ
When is Compugen (CGEN) presenting at the Single Cell Genomics 2025 Conference?
What research will Compugen present at the Single Cell Genomics Conference?
Who will be presenting Compugen's research at the Single Cell Genomics Conference?
Where can investors access Compugen's Single Cell Genomics Conference presentation?
